Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 41–60 of 1,190 studiesSort:

Active, not recruitingInterventional · Not applicableNCT03556085 ↗
Clinical Evaluation of the Serenity River Stent System to Treat Idiopathic Intracranial Hypertension
Marc Joshua DinkinPI
Intervention
Device: Venous sinus stenting (Serenity River)
Dates
Aug 2018 – Oct 2022

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 41–60 of 1,190 studiesSort:

Active, not recruitingInterventional · Not applicableNCT03556085 ↗
Clinical Evaluation of the Serenity River Stent System to Treat Idiopathic Intracranial Hypertension
Marc Joshua DinkinPI
Intervention
Device: Venous sinus stenting (Serenity River)
Dates
Aug 2018 – Oct 2022

Phase 2/3

Early phase 13

Harini Sarva21
Ashish Saxena20
Cora Sternberg20
Ellen K. Ritchie18
Ruben Niesvizky16
Dana Jeremy Lukin14
Evelyn M. Horn14
Pinkal Desai14
Ellen J Scherl13
Daniel W Skupski12
Eleni Andreopoulou12
Jim W. Cheung12
Jia Ruan12
Massimo Cristofanilli12
Sujit Sheth12
Catherine Butkus Small11
James E. Ip11
John Allan11
Anna C Pavlick10
Alexander Ja-Ho Chou10
Aliza B Solomon10
Alpana P. Shukla10
Marshall J. Glesby10
Anna Podolanczuk9
Barbara Ma9
Catherine McGuinn9
Silvia Chiara Formenti9
Hani Lamie Ashamalla9
Kristen Marks9
Robert J. Kaner9
Shari Lipner9
Maria Teresa DeSancho8
Samuel Kim8
Andrew F. Alexis7
Erin Mulvey7
Evelyn Cantillo7
Jean W. Pape7
Sebastian A. Mayer7
Brian DeRubertis6
Conor Liston6
Darshana M Dadhania6
David M Nanus6
Joseph M Scandura6
Lok W. Yung6
Mehraneh Dorna Jafari6

Neurological Surgery19

Cardiothoracic Surgery17

Urology15

Rehabilitation Medicine13

Population Health Sciences9

Otolaryngology Head and Neck Surgery7

Pathology and Laboratory Medicine1

Pharmacology1

Show fewer

Carcinoma, Non-Small-Cell Lung27
Multiple Myeloma27
Colitis, Ulcerative26
Crohn Disease26
Myelodysplastic Syndromes26
Recurrence25
Atrial Fibrillation23
Neoplasm Metastasis23
Obesity23
Parkinson Disease21
COVID-1920
Colorectal Neoplasms18
Depression18
Cardiovascular Diseases17
Hematologic Neoplasms17
HIV Infections16
Non-alcoholic Fatty Liver Disease15
Overweight15
Melanoma13
Idiopathic Pulmonary Fibrosis12
Inflammatory Bowel Diseases12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lung Neoplasms12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Hypertension11
Myeloproliferative Disorders11
Alzheimer Disease10
Coronary Artery Disease10
Hypertension, Pulmonary10
Leukemia, Myelomonocytic, Chronic10
Stroke10
Urinary Bladder Neoplasms10
Cognitive Dysfunction9
Leukemia9
Lung Diseases, Interstitial9
Pulmonary Arterial Hypertension9
Burkitt Lymphoma8
Carcinoma, Renal Cell8
Chronic Pain8
Fibrosis8
Lymphoma, Follicular8
Lymphoma, Large B-Cell, Diffuse8
Adenocarcinoma Of Esophagus7
Anemia7

Radiation

Diagnostic test22

Dietary supplement14

Combination product11

Genetic6

Sponsor

Serenity Medical Inc.

Idiopathic Intracranial Hypertension

RecruitingInterventional · Phase 1/2NCT03556228 ↗

A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma

Ashish SaxenaPI

Intervention: Drug: VMD-928 100 mg Tablet · Drug: VMD-928 Tablet and Pembrolizumab (200 mg)
Dates: Jun 2018 – Dec 2027 (est.)
Sponsor: VM Oncology, llc

Head and Neck CarcinomaAdenoid Cystic CarcinomaLung Cancer+22 more

Active, not recruitingInterventional · Not applicableNCT03561220 ↗

A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

Baoqing LiPI

Intervention: Radiation: Standard of Care IMRT (Photon) · Radiation: Standard of Care Proton Therapy · Radiation: Proton Arm 1: Standard Proton Therapy · Radiation: Proton Arm 2: Hypofractionated Proton Therapy
Dates: Jul 2018 – Feb 2026
Sponsor: University of Florida Health - Jacksonville

Prostate Cancer

Active, not recruitingInterventional · Phase 3NCT03568383 ↗

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)

Jean W. PapePI

Intervention: Drug: Delamanid (DLM) · Drug: Isoniazid (INH) · Dietary supplement: Pyridoxine (vitamin B6)
Dates: Jun 2019 – Nov 2026 (est.)
Sponsor: National Institute of Allergy & Infectious Diseases

Tuberculosis, MDR

Active, not recruitingInterventional · Phase 2NCT03600701 ↗

A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer

Ashish SaxenaPI

Intervention: Drug: Atezolizumab · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Cobimetinib · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging
Dates: Nov 2018 – Jul 2025· Results posted
Sponsor: National Cancer Institute

Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell Carcinoma+1 more

Active, not recruitingInterventional · Phase 3NCT03602859 ↗

A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Eloise ChapmanPI

Intervention: Drug: Niraparib · Drug: Dostarlimab (TSR-042) · Drug: Standard of care · Drug: Dostarlimab-Placebo · Drug: Niraparib-Placebo
Dates: Oct 2018 – Oct 2024· Results posted
Sponsor: Tesaro, Inc.

Ovarian NeoplasmsOvarian, Fallopian Tube and Primary Peritoneal Carcinoma

Active, not recruitingInterventional · Phase 2NCT03604198 ↗

An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome

Georgiana Alina DobriPI

Intervention: Drug: relacorilant
Dates: May 2018 – Dec 2026 (est.)
Sponsor: Corcept Therapeutics Incorporated

Cushing Syndrome

Active, not recruitingInterventional · Phase 2/3NCT03604991 ↗

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Manish A ShahPI

Intervention: Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Biological: Ipilimumab · Biological: Nivolumab · Drug: Paclitaxel · Procedure: Positron Emission Tomography · Radiation: Radiation Therapy
Dates: May 2019 – Mar 2027 (est.)
Sponsor: ECOG-ACRIN Cancer Research Group

Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8+5 more

RecruitingInterventional · Phase 2NCT03606967 ↗

Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer

Massimo CristofanilliPI

Intervention: Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Biological: Durvalumab · Drug: Gemcitabine Hydrochloride · Procedure: Magnetic Resonance Imaging · Drug: Nab-paclitaxel · Biological: Personalized Synthetic Long Peptide Vaccine · Drug: Poly ICLC · Biological: Sacituzumab Govitecan · Biological: Tremelimumab
Dates: Apr 2021 – Dec 2026 (est.)
Sponsor: National Cancer Institute

Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaMetastatic Triple-Negative Breast Carcinoma

Active, not recruitingInterventional · Not applicableNCT03621644 ↗

Prospective Phase II Study of Stereotactic Magnetic Resonance Imaging (MRI) Guided On-table Adaptive Radiation Therapy (SMART) for Patients With Borderline or Inoperable Locally Advanced Pancreatic Cancer

John NgPI

Intervention: Radiation: Stereotactic MRI-guided On-table Adaptive Radiation Therapy
Dates: Jan 2019 – Aug 2022
Sponsor: ViewRay Technologies, Inc

Pancreatic Cancer

Active, not recruitingInterventional · Phase 3NCT03653507 ↗

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Manish A ShahPI

Intervention: Drug: zolbetuximab · Drug: oxaliplatin · Drug: capecitabine · Drug: placebo
Dates: Nov 2018 – Oct 2022· Results posted
Sponsor: Astellas Pharma Global Development, Inc.

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more

RecruitingInterventional · Phase 1NCT03666000 ↗

A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Sebastian A. MayerPI

Intervention: Biological: Azer-cel · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: IL-2 · Drug: Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib
Dates: Mar 2019 – Jun 2027 (est.)
Sponsor: Precision BioSciences, Inc.

Non-Hodgkin LymphomaB-cell Acute Lymphoblastic LeukemiaChronic Lymphocytic Leukemia+1 more

RecruitingInterventional · Not applicableNCT03671889 ↗

Assessment of Safety and Efficacy of ExAblate Blood-Brain Barrier Disruption for the Treatment of Patients With Probable Alzheimer's Disease

Michael G KaplittPI

Intervention: Device: Blood Brain Barrier (BBB) Disruption
Dates: Sep 2018 – Jan 2028 (est.)
Sponsor: InSightec

Alzheimer Disease

RecruitingInterventional · Phase 3NCT03678025 ↗

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Douglas S ScherrPI

Intervention: Drug: Abiraterone · Drug: Bicalutamide · Drug: Degarelix · Drug: Docetaxel · Drug: Flutamide · Drug: Goserelin Acetate · Drug: Histrelin Acetate · Drug: Leuprolide Acetate · Drug: Nilutamide · Procedure: Orchiectomy · Drug: Prednisone · Other: Quality-of-Life Assessment · Radiation: Radiation Therapy · Procedure: Radical Prostatectomy · Drug: Triptorelin
Dates: Sep 2018 – Apr 2033 (est.)
Sponsor: Southwest Oncology Group

Castration Levels of TestosteroneMetastatic Prostatic AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more

Active, not recruitingInterventional · Phase 3NCT03682068 ↗

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.

Scott T. TagawaPI

Intervention: Drug: Durvalumab · Drug: Tremelimumab · Drug: Cisplatin + Gemcitabine · Drug: Carboplatin + Gemcitabine
Dates: Sep 2018 – Jun 2026
Sponsor: AstraZeneca Pharmaceuticals LP

Unresectable Locally Advanced Urothelial CancerMetastatic Urothelial Cancer

Enrolling by invitationInterventional · Phase 3NCT03683186 ↗

A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)

Evelyn M. HornPI

Intervention: Drug: Ralinepag
Dates: Sep 2019 – Dec 2026 (est.)
Sponsor: United Therapeutics

PAHPulmonary HypertensionPulmonary Arterial Hypertension+8 more

Active, not recruitingInterventional · Phase 2/3NCT03701308 ↗

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Gail J RobozPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Cytarabine · Drug: Daunorubicin · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan · Drug: Uproleselan
Dates: Mar 2019 – Oct 2024· Results posted
Sponsor: Alliance for Clinical Trials in Oncology

Acute Myeloid Leukemia

Active, not recruitingInterventional · Phase 2NCT03712202 ↗

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

Jia RuanPI

Intervention: Drug: Bleomycin · Drug: Brentuximab Vedotin · Drug: Dacarbazine · Drug: Doxorubicin · Biological: Nivolumab · Other: Quality-of-Life Assessment · Drug: Vinblastine
Dates: Nov 2018 – Nov 2024· Results posted
Sponsor: City of Hope National Medical Center

Ann Arbor Stage I Hodgkin LymphomaAnn Arbor Stage I Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma+11 more

Active, not recruitingInterventional · Phase 2NCT03722407 ↗

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

Gail J RobozPI

Intervention: Drug: Ruxolitinib
Dates: Aug 2019 – Sep 2022· Results posted
Sponsor: H. Lee Moffitt Cancer Center & Research Institute

Chronic Myelomonocytic LeukemiaLeukemia

Active, not recruitingInterventional · Phase 3NCT03725059 ↗

A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)

Eleni AndreopoulouPI

Intervention: Biological: Pembrolizumab (K) · Drug: Placebo (P) · Drug: Paclitaxel (X) · Drug: Doxorubicin (A) · Drug: Epirubicin (E) · Drug: Cyclophosphamide (C) · Drug: Endocrine therapy · Radiation: Radiation therapy · Procedure: Surgery
Dates: Dec 2018 – Jan 2031 (est.)
Sponsor: Merck & Co., Inc.

Breast Cancer

‹ Prev 1 2 3 4 5…56 57 58 59 60 Next ›